GHK-Cu Dosage: What the Research Reports

What is GHK-Cu, and why does "dosage" work differently here?

GHK-Cu dosage is usually described as a concentration, not a milligram amount, because this copper-binding tripeptide is active at trace levels.

GHK stands for glycyl-histidyl-lysine, a three-part peptide that binds copper(II) with high affinity. It was first isolated from human plasma in 1973 as an activity that made aged liver tissue behave more like younger tissue (Pickart et al., 2012). The review by Pickart and Margolina, 2018 describes it as a naturally circulating molecule that signals to skin cells and helps move copper into tissue. Because it works as a signaling molecule at trace levels, the useful question is often "what concentration was studied," not "how many milligrams were given." That is a different frame from most peptides, and it is why searches for a single GHK-Cu dosage number rarely match what the literature actually reports.

What concentrations does the research actually report?

Published fibroblast and wound-healing work describes GHK-Cu activity in the nanomolar range, far below typical drug doses (Pickart and Margolina, 2018).

The ranges below reflect what published studies and commonly studied research protocols report. This is educational, not a prescription or a personal recommendation. Each row lists the model, the reported concentration or form, the route, and the source. These are research-reported figures, not instructions.

Note on units: a concentration like 0.01 nM equals 10 picomolar, so the lowest active levels the review reports sit in the tens-of-picomolar range, while most reported activity is at 1 to 100 nM. The strongest numbers describe cells, natural blood levels, and topical products. There is no controlled human trial that pins a systemic milligram dose to an outcome.

Is there a standard GHK-Cu dosage for people?

No. There is no established human GHK-Cu dosage, because the best-supported evidence is topical and cell-based, and the review frames GHK-Cu as a low-concentration signaling molecule rather than a milligram-dosed drug (Pickart and Margolina, 2018).

Topical products vary in how much GHK-Cu they contain, and the review treats it as a skin-active ingredient rather than something governed by a fixed dosing standard. The one well-known human clinical study used a topical gel with a metered dose on diabetic neuropathic ulcers, not a systemic milligram protocol (Mulder et al., 1994). Because there is no regulatory dosing benchmark and no completed human dose-finding trial for systemic use, any figure presented online as "the" GHK-Cu dose is not backed by controlled human data. A personal decision about form or amount is a clinician question.

What about injectable or subcutaneous GHK-Cu?

Injectable GHK-Cu is off-label and thinly studied, with no completed human trials establishing a safe or effective dose (human data limited).

The human evidence base is mostly topical, cosmetic, and mechanistic, so injectable protocols shared in forums do not rest on published human dosing studies. Copper is also a trace mineral the body regulates closely: absorption and biliary release keep copper balanced, and health authorities set an upper intake limit for adults (NIH Office of Dietary Supplements, Copper fact sheet). That is one reason systemic use raises safety questions a lab review of cell and skin data does not answer. This page does not provide an injection amount, schedule, or method. That routes to a qualified clinician who can weigh individual context.

How is GHK-Cu thought to work?

The review describes GHK-Cu as a copper-delivery and gene-signaling molecule that influences skin remodeling, antioxidant, and repair-related pathways at low concentrations (Pickart and Margolina, 2018).

Pickart and Margolina, 2018 report that GHK can shift the expression of thousands of human genes: in their analysis, a large share of genes changed by at least 50%, with more genes turned up than down. It is associated with collagen and elastin support, antioxidant activity, and anti-inflammatory signaling in the models reviewed. These are described mechanisms and cell or skin observations. They are not proof of a clinical outcome in a person, and the review does not translate them into a personal dose.

What does the research report about safety?

Published safety information for GHK-Cu is mostly limited to topical cosmetic and wound contexts, and systemic or injectable safety in humans is not well characterized (human data limited).

Within the cosmetic and mechanistic literature summarized by Pickart and Margolina, 2018, GHK-Cu is discussed as a well-studied topical ingredient, and the 1994 diabetic-ulcer trial reported it was tolerated as a topical gel (Mulder et al., 1994). That does not extend to injectable or systemic use, where controlled human safety data is absent. Because copper handling is tightly regulated and individual health status matters, safety questions are best reviewed with a clinician rather than inferred from skin-active research.